Predictcan – Leading-Edge Solutions for Precision Medicine

About

About

ABOUT

The 3-One concept:
one disease - one patient - one therapeutic protocol
for the best chance to cure

PredictCan Biotechnologies is a startup driven by the willingness to advance and to improve precision medicine in oncology. Because cancer is a complex and heterogeneous disease that leads to major public health and economic issues worldwide, we believe that accurate and sensitive solutions are urgently needed to support patients and save lives.

At PredictCan Biotechnologies, we employ our long-lasting expertise in translational research and precision medicine to deliver innovative tools for cancer detection and treatment. We are continually reevaluating and adapting our products to medical inquiries to provide cutting-edge technologies to patients, clinicians, and pharmaceutical industries supporting their combat against cancer.

We envision a future in which our company as a companion of the health system, brings a personalized care solution to each patient increasing their likelihood to be cured.

Meet the Team

Leadership Team

Hong Tuan DUONG, PhD - Predictcan

Hong Tuan DUONG, PhD

Chief Executive Officer

Dr. Hong Tuan DUONG is a cofounder of PredictCan Biotechnologies. He received his PhD in Pharmacology and Cell Biology from the University of Strasbourg and worked for eighteen years at the University of Basel in Switzerland developing and supervising translational research projects on innate immunity and liver diseases. Lately, he brought his expertise to the INSERM unit at the University of Strasbourg pursuing his efforts in precision oncology.

Sara CHERRADI, PhD

Chief Technical Officer

Dr. Sara CHERRADI is a cofounder of PredictCan Biotechnologies. She received her PhD in Cancer Biology from the University of Montpellier and completed a postdoctoral fellowship at the University of Strasbourg where she developed as a R&D leader solid expertise on patient-derived models for anticancer preclinical drug development and precision medicine.

Nicolas TAULET, PhD

Project Manager

Dr Nicolas TAULET received his PhD in Cell Biology from the University of Montpellier. After his PhD, he has worked as postdoc and project manager for more than twelve years at CNRS/University of Montpellier and at The Scripps Research Institute in San Diego. He acquired a solide expertise in cancer and cell biology as well as strong skills in cutting-edge microscopy.